Indoco Remedies · NSE: INDOCO · BSE: 532612
Q1 FY21 results · Apr–Jun 2020
Indoco Remedies reported revenue from operations of ₹275.86 crore and net profit of ₹17.04 crore for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 275.86 | — | — | 271.99 | +1.4% |
| Other income | 0.26 | — | — | 0.50 | −48.0% |
| Total income | 276.12 | — | — | 272.49 | +1.3% |
| Profit before tax | 24.03 | — | — | 7.76 | +209.7% |
| Net profit for the period | 17.04 | — | — | 5.36 | +217.9% |
| EPS, basic (₹) | 1.85 | — | — | 0.58 | +219.0% |
| Net margin (%) | 6.2 | — | 2.0 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 275.86 | 252.67 | +9.2% | 272.02 | +1.4% |
| Other income | 0.26 | 0.64 | −59.4% | 0.49 | −46.9% |
| Total income | 276.12 | 253.31 | +9.0% | 272.51 | +1.3% |
| Profit before tax | 24.24 | 0.28 | 87x | 7.80 | +210.8% |
| Net profit for the period | 17.23 | 2.18 | +690.4% | 5.40 | +219.1% |
| EPS, basic (₹) | 1.87 | 0.24 | +679.2% | 0.59 | +216.9% |
| Net margin (%) | 6.2 | 0.9 | 2.0 |
Consolidated
- Filed with BSE
- 11 Aug 2020, 19:35 IST
- Board meeting
- 11 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Aug 2020, 19:35 IST
- Board meeting
- 11 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE